Experimental Medicine INitiative to Explore New Therapies

新的靶点、方法和工具，用于评估传统上对药物兴趣不高的疾病。重要的是，该计划将重点关注与GSK有现有合作伙伴关系的学术中心，并证明与GSK有富有成效的工作关系，以确保建立一个灵活、反应迅速的网络。这将使项目得以迅速实施，并以及时和具有成本效益的方式成功交付。每个核心中心也有一个已建立的生物医学研究中心（或其苏格兰同等机构），并将在疾病领域提供互补的专业知识，可以充分利用GSK在英国的积极研发工作，即：免疫炎症，呼吸系统疾病和纤维化。参与中心的紧密合作将促进机构间联盟的形成，参与网络的前提是合作和共享学术专业知识和资源的意愿，有可能接触到更大的患者群体。所有合作伙伴还致力于确保在每个项目中都有一个培训元素，以培养下一代研究人员，他们灵活，能够跨越边界，在学术和行业环境中工作。项目计划将由学术界和葛兰素史克的研究人员共同制定。该计划成功的关键在于，GSK预先承诺提供独特的靶点和药物发现专业知识、现有的许可药物和临床就绪化合物，以及获得最先进的平台技术。所有临床研究都将由GSK全额资助，从而使theNetwork受益于其全面的运营、监管、分析和统计能力。重要的是，该网络将只关注目前不在GSK投资组合活动范围内的项目，尽管它们可能代表未来药物开发机会的来源。因此，杰出人才倡议的主要原则是：？加强对高未满足需求疾病的了解，目前GSK产品组合的重点之外？参与机构之间的合作，以提供最好的科学？里程碑驱动的方法来进行精心设计的实验医学项目，以增加对人类疾病基本机制的理解？与MRC和葛兰素史克相匹配，在英国提供实物、资金、建筑专业知识和基础设施？学术合作伙伴与GSK之间的培训和知识技能交流？本文件概述了卓越环境规划的愿景、拟议的工作程序、治理和预期成果，并选择了一些说明性的范例项目，以展示该计划的潜在价值和影响。

new targets and approaches and tools for the evaluation of diseases for which pharmaceuticalinterest has traditionally been low.Importantly, this initiative will focus on academic centres with existing partnerships and evidence ofa productive working relationship with GSK to ensure an agile and responsive network. This willallow both rapid implementation and the successful delivery of projects in a timely and costeffectivemanner. Each of the core centres also has an established Biomedical Research Centre (or itsScottish equivalent), and will provide complementary expertise in disease areas that can take fulladvantage of the active UK-based GSK R&D effort, namely: immuno-inflammation, respiratorydisease, and fibrosis. The close alignment of the participating centres will foster the formation ofinter-institutional alliances and participation in the Network is predicated on a willingness tocollaborate and share academic expertise and resource, with the potential to access larger patientcohorts. All partners are also committed to ensuring that there is a training element within eachproject in order to develop the next generation of researchers who are flexible and able to crossboundaries and work in both the academic and industry environments.Projects plans will be developed jointly by the academic and GSK investigators. Vital to the success ofthe initiative is the up-front commitment GSK has made to providing unique target and drugdiscovery expertise, existing licensed drugs and clinic-ready compounds, and access to state-of-theart platform technologies. All clinical studies will be fully sponsored by GSK, thereby allowing theNetwork to benefit from its full operational, regulatory, analytical and statistical capabilities.Importantly, the Network will focus solely on projects which currently sit outside GSK’s portfolioactivities, although they could potentially represent a source of future drug developmentopportunities.Hence the key principles of the EMINENT initiative are:? Enhancing disease understanding in diseases of high unmet need, outside the current focus ofthe GSK portfolio? Collaboration across participating institutions to deliver the best science? Milestone-driven approach to conduct well designed experimental medicine projects to increaseunderstanding of the fundamental mechanisms of human disease? Matched MRC and GSK, in-kind, funding, building expertise and infrastructure in the UK? Training and the exchange of knowledge and skills between academic partners and GSK? Prompt publication of dataThis document outlines the vision, proposed working procedures, governance, and expectedoutcomes of EMINENT, together with a selection of illustrative, exemplar projects to showcase thepotential value and impact of this initiative.